Organoid Technology: A New Frontier in Biomedical Research and Public Health

Chronic diseases represent a leading global health challenge, accounting for over 70 percent of deaths worldwide and posing a growing burden with aging populations and lifestyle shifts. Traditional approaches to disease treatment and research are facing limitations, driving the need for more precise and efficient biomedical solutions. Organoid technology, a revolutionary advancement in the biomedical field, offers a novel platform for investigating disease mechanisms, accelerating clinical translation, and potentially reshaping public health strategies.

What are Organoids?

Organoids are miniature, self-organizing three-dimensional structures grown in vitro that closely mimic the key features of normal or pathological human tissues. Their ability to recapitulate complex organ structures and functions has led to widespread recognition as a breakthrough technology in biological research.

Applications of Organoid Technology

Organoids provide a transformative platform for several critical applications:

• Drug Effectiveness and Safety Testing: Organoids enhance the predictive reliability of drug development, toxicity screening, and personalized medicine.
• Disease Modeling: By replicating the structures and functions of diseased organs, organoids allow researchers to study disease progression and identify potential therapeutic targets.
• Personalized Medicine: Organoids can be derived from patient-specific cells, enabling the development of tailored treatment strategies.
• Rare Disease Research: Organoids empower the development of targeted therapies for rare diseases where traditional research methods are often limited.

Convergence with Emerging Technologies

Organoid technology is not isolated; it converges with multiple scientific disciplines to drive innovation:

• Biomaterials: Providing the scaffolding for organoid growth.
• Microfluidics: Enabling precise control of the organoid microenvironment.
• Artificial Intelligence (AI): Driving drug discovery and enhancing data analysis.

The integration of organoid data systems with AI is propelling the technology toward greater intelligence and standardization. By converging multimodal data with advanced analysis, researchers can deepen mechanistic insights, enhance the predictive accuracy of drug responses, and refine personalized treatment strategies.

Addressing Ethical Concerns and Regulatory Landscape

With increasing global regulations on animal experimentation, organoids offer a compelling alternative – highly biomimetic human models that minimize animal use while advancing ethical science. This advantage is driving their increasing international importance.

China has made significant strides in regulating and promoting organoid technology. Key milestones include:

• January 2024: The National Medical Products Administration recognized organoids as supportive tools for evaluating stem cell products.
• June 2025: Organoids were officially designated as non-clinical models for rare disease drug development.
• October 2025: New regulations on emerging biomedical technologies formally advanced China’s organoid technology.

China’s Position and Future Directions

China has rapidly advanced in organoid research, ranking second worldwide in publication output and leading in patent filings. Domestic companies have successfully developed diverse organoid models, integrating outcomes into the research and development pipelines of both Chinese and global pharmaceutical companies.

To further strengthen its position, China is prioritizing the establishment of a national-level, high-standard organoid repository and sharing platform to ensure autonomous and controllable management of strategic biological resources. Developing a technical standard and ethical governance system is similarly crucial for strengthening China’s voice in international rule-setting.

Establishing a human-relevant and autonomously controlled organoid biobank is a strategic priority. While progress has been made, including the Ministry of Education’s approval of the Organoid Resource Bank at Nanchang University, systematic national planning and coordinated promotion are still needed.

Global Landscape

The United States, European nations, and Japan have strategically invested in organoid applications in drug development, animal welfare, and regenerative medicine, positioning themselves at the forefront of this transformative field. The US National Institutes of Health established its first national-level standardized organoid modeling center in September 2025, and the United Kingdom government committed £75.9 million ($101.67 million) in November 2025 to replace animal tests with organoid models and accelerate the development of a global resource network.

Looking Ahead

With systematic planning and coordinated advancement, organoid technology promises to drive high-quality transformation in the biopharmaceutical industry, ushering in a new chapter for global healthcare. Integrating organoid technology into key national initiatives will strengthen China’s competitive edge and leadership in this critical field.